Drug Safety Research Unit
Remdesivir has a “favourable” benefit/risk profile in COVID-19 but more data needed, DSRU review argues
October 5, 2020Research and Development, Sales and Marketing COVID-19, Drug Safety Research Unit, pharma, remdesivir
Southampton’s Drug Safety Research Unit (DSRU) has released a systematic benefit/risk analysis of Gilead’s antiviral drug remdesivir in the treatment …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
